ENDOLOGIX

Endologix Announces Completion of Enrollment in the TORUS 2 Study for PAD in SFA

Retrieved on: 
Tuesday, November 23, 2021
Surgery, Medical Devices, Health, Clinical Trials, Cardiology, IDE, Trial of the century, CEO, Safety, Technology, Acquisition, University of California, San Francisco, Aortic aneurysm, Clinical trial, University, FSVM, Master of Science, Moyamoya disease, FACC, Vascular disease, EVAR, Division, PAD, DETOUR, Adventist Health, Medical imaging, Pharmaceutical industry, Endologix, Deerfield Management, ENDOLOGIX, DEERFIELD MANAGEMENT

The study was designed to evaluate safety and effectiveness of the TORUS Stent Graft System in the treatment of obstructive atherosclerotic lesions of the native SFA and proximal popliteal arteries.

Key Points: 
  • The study was designed to evaluate safety and effectiveness of the TORUS Stent Graft System in the treatment of obstructive atherosclerotic lesions of the native SFA and proximal popliteal arteries.
  • We especially appreciate the strong efforts of our clinical trial sites to enroll this trial efficiently and with high quality.
  • The completion of enrollment for TORUS 2 is a significant milestone in a clinically-challenging area of vascular disease, said Matt Thompson, MD, President and CEO of Endologix.
  • The TORUS stent-graft is also a pivotal component of the DETOUR procedure, a totally percutaneous femoropopliteal bypass, currently under clinical investigation.

Endologix Initiates Randomized Study of ALTO® Abdominal Stent Graft System

Retrieved on: 
Wednesday, September 29, 2021
Surgery, Medical Devices, Health, Clinical Trials, Cardiology, Technology, Gauge, Abdominal aortic aneurysm, Hospital, Sentara Norfolk General Hospital, III, Patient, MD, EVAS, EVAR, JAGUAR, Vascular disease, Freedom, ALTO, Occlusion, AAA, Time, Christian philosophy, Aortic aneurysm, Medical imaging, the ALTO Abdominal Stent Graft System, Endologix, Deerfield Management, THE ALTO ABDOMINAL STENT GRAFT SYSTEM, ENDOLOGIX, DEERFIELD MANAGEMENT

Endologix LLC , a leader in the treatment of vascular disease, today announced that the first patient has been enrolled in the companys JAGUAR study to compare outcomes for the companys ALTO Abdominal Stent Graft System to other commercially available endovascular aneurysm repair (EVAR) devices for the treatment of abdominal aortic aneurysm (AAA).

Key Points: 
  • Endologix LLC , a leader in the treatment of vascular disease, today announced that the first patient has been enrolled in the companys JAGUAR study to compare outcomes for the companys ALTO Abdominal Stent Graft System to other commercially available endovascular aneurysm repair (EVAR) devices for the treatment of abdominal aortic aneurysm (AAA).
  • The study is designed for at least 300 patients to be randomly allocated to the ALTO cohort and 150 to the comparator group.
  • Featuring a unique, patented, sealing technology, the ALTO Abdominal Stent Graft System is the latest generation of innovative therapies for AAA patients.
  • Endologixs current commercial EVAR products include the AFX2 device and the ALTO Abdominal Stent Graft System.

Endologix LLC Announces Launch of ALTO® Abdominal Stent Graft System in Canada and Argentina

Retrieved on: 
Tuesday, May 11, 2021
Health, Surgery, Cardiology, Medical devices, Interventional radiology, Medical specialties, Vascular surgery, Medicine, Endovascular aneurysm repair, Clinical medicine, Evar, Stent, XC2, Abdominal Aortic Aneurysm (AAA), the ALTO Abdominal Stent Graft System, Endologix’s Product Portfolio, Endologix, ABDOMINAL AORTIC ANEURYSM (AAA), THE ALTO ABDOMINAL STENT GRAFT SYSTEM, ENDOLOGIX’S PRODUCT PORTFOLIO, ENDOLOGIX

b"Endologix LLC , a leader in the treatment of vascular disease, today announced the first implant of its ALTO\xc2\xae Abdominal Stent Graft in Canada following recent approval from Health Canada.

Key Points: 
  • b"Endologix LLC , a leader in the treatment of vascular disease, today announced the first implant of its ALTO\xc2\xae Abdominal Stent Graft in Canada following recent approval from Health Canada.
  • View the full release here: https://www.businesswire.com/news/home/20210511005366/en/\nFeaturing a unique, patented, sealing technology, the ALTO Abdominal Stent Graft System is the latest generation in polymer-based therapies for AAA patients.
  • ALTO utilizes a low-profile delivery system and, unlike standard EVAR devices, features an exclusive conformable sealing ring that molds in-situ to the patient\xe2\x80\x99s specific aortic neck anatomy.
  • The company\xe2\x80\x99s current commercial EVAR products include the AFX\xc2\xae2 device and the ALTO\xc2\xae Abdominal Stent Graft System.